Welcome to our dedicated page for OKYO PHARMA SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma director Bernard Denoyer received an option grant for 3,500 shares of OKYO Pharma Ltd common shares. The options have an exercise price of $1.85 per share and are exercisable into 3,500 common shares. After this grant, Denoyer holds options on 35,190 shares in total. The options are scheduled to expire on June 8, 2036, indicating a long-dated, compensation-related award rather than an open-market share purchase or sale.
OKYO Pharma Ltd director John P. Brancaccio received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options were awarded on June 8, 2026 and are scheduled to become exercisable on June 8, 2027, expiring on June 8, 2036. Following this compensation-related grant, Brancaccio holds options over 138,394 shares in total.
OKYO Pharma Ltd director Simon Willy Jules received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options relate to common shares and increase his directly held derivative position to 135,502 options following the transaction. The options become exercisable on June 8, 2027 and are scheduled to expire on June 8, 2036, indicating a long-term, compensation-related award rather than an open-market share purchase or sale.
OKYO Pharma Ltd reported that Chief Financial Officer Keeren Rameshchandra Shah received a grant of options covering 40,000 common shares at an exercise price of $1.85 per share. These options are exercisable beginning on June 8, 2027 and expire on June 8, 2036. Following this award, the filing shows 544,819 derivative securities held directly, indicating this is a compensation-related grant rather than an open-market purchase.
OKYO Pharma Ltd director and 10% owner Gabriele M. Cerrone reported an indirect acquisition of 300,000 shares of common stock. The shares were received as a grant or award at a reference price of $1.72 per share and are held through Panetta Partners Limited.
Following this transaction, indirect holdings associated with Cerrone total 10,826,416 shares of OKYO Pharma common stock, indicating this was a relatively small addition to an already large position.
OKYO Pharma Ltd director Bernard Denoyer filed an initial ownership report showing multiple option grants over OKYO common stock. The options have exercise prices ranging from $1.46 to $2.13 per share and expire between 2033 and 2035. Examples include options over 3,750 underlying shares at $1.50 expiring in 2035 and options over 3,334 underlying shares at $1.46 expiring in 2034.
OKYO Pharma Ltd director Simon Willy Jules has filed a Form 3 reporting his initial ownership in the company. He holds 6,435 shares of common stock directly and 8,948 shares indirectly through his spouse. He also reports multiple option awards over common stock, including grants covering 12,500 shares at an exercise price of $1.50 per share and 5,000 shares at $1.65 per share, with expiration dates running from 2033 to 2035. These positions show his existing equity and option exposure rather than new market transactions.
OKYO Pharma Ltd director John P. Brancaccio has filed an initial ownership report showing his equity position in the company. He directly holds 30,201 shares of common stock, plus multiple option awards over OKYO common shares with exercise prices between $1.46 and $2.13 per share and expirations ranging from 2033 to 2035. These options vest in staggered annual tranches from 2024 through 2029, giving him long‑term, option-based exposure in addition to his current shareholdings.
OKYO Pharma Ltd’s chief financial officer, Keeren Rameshchandra Shah, reports his existing equity stake in the company. He holds 16,667 shares of common stock directly. The filing also lists multiple option awards over common stock, including grants for 31,250 shares at a 1.50 exercise price expiring in 2035 and 25,193 shares at a 2.13 exercise price expiring in 2033.
OKYO Pharma Ltd filed a Form 3 showing that Chief Executive Officer Robert John Dempsey holds four stock option positions over its common stock. Each option position relates to 400,000 shares of common stock at an exercise price of $2.2300 per share.
The options have staggered exercise dates on January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030, and all are scheduled to expire on January 2, 2036. The filing records these as existing holdings rather than new market transactions.